IMAGENEBIO INC (IMA:NASDAQ)
$5.91 0.13 (2.2491%)
Analysed IMAGENEBIO INC (IMA:NASDAQ) News Sources
ImageneBio Announces $30 Million Private Placement
13-04-2026
yahoo.com
Image Resources NL (ASX:IMA) Is About To Turn The Corner
01-04-2026
yahoo.com
Imax announces $28M opening weekend for Amazon/MGM/s ‘Project Hail Mary’
24-03-2026
yahoo.com
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17-03-2026
yahoo.com
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
10-03-2026
yahoo.com
ImageneBio to Participate in Leerink Global Healthcare Conference
26-02-2026
yahoo.com
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
10-02-2026
yahoo.com
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap
31-12-2025
yahoo.com
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation
15-11-2025
yahoo.com
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
12-11-2025
yahoo.com
What is the current price of IMAGENEBIO INC (IMA:NASDAQ)?
The current price of IMAGENEBIO INC (IMA:NASDAQ) is $5.91.
IMAGENEBIO INC (IMA:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMAGENEBIO INC (IMA:NASDAQ) since the previous trading day is $0.13.
IMAGENEBIO INC (IMA:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMAGENEBIO INC (IMA:NASDAQ) since the previous trading day is 2.2491%.
What is the most recent average sentiment score for IMAGENEBIO INC (IMA:NASDAQ)?
The most recent average sentiment score for IMAGENEBIO INC (IMA:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for IMAGENEBIO INC (IMA:NASDAQ)?
The most recent sentiment for IMAGENEBIO INC (IMA:NASDAQ) is .
SEC-8K** Filing Available For IMAGENEBIO INC (IMA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.